Why is DHL suspending high-value US shipments?
How are Trump tariffs impacting US small businesses?
What caused Tesla’s recent Cybertruck production cuts?
Why did Capital One get approval to buy Discover?
How is the Russia-Ukraine Easter ceasefire affecting markets?
What is behind UnitedHealth CEO’s recent alarm?
Why is the Supreme Court blocking some deportations?
How are US tariffs altering global supply chains?
Why is Tesla stock facing volatility this month?
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-oral-glp-1-receptor-agonist
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being…
This story appeared on pfizer.com, 2025-04-15 16:24:45.376000.